Rectal cancer treatment with chemo, radiation, and camrelizumab
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of long-term chemotherapy plus radiation along with the immunotherapy drug camrelizumab for patients with rectal cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor and possibly avoid the need for a permanent colostomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your rectal cancer must be at a stage where it hasn't spread to other parts of the body (like the liver or lungs). It may be locally advanced or low in the rectum, requiring surgery to save the anus.
- You must be in good enough health to be up and about (ECOG 0 or 1), and have adequate blood cell counts and organ function.
- You cannot have had radiation or immunotherapy (like checkpoint inhibitors) for your rectal cancer before.
- You must not have active autoimmune disease, severe heart or lung conditions, or other recent cancers (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.